Matt Kapusta, uniQure
June 22, 2021 02:51 PM EDTUpdated 04:27 PM
Deals
FDA+

With FDA fil­ing for key gene ther­a­py pushed back 6 months, uniQure opens the pock­et­book to re­fresh the pipeline

Kyle Blankenship

Once fac­ing a ma­jor set­back for its lead gene ther­a­py pro­gram for he­mo­phil­ia B, uniQure saw a sliv­er of light when the FDA lift­ed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times